Drugmakers cut pricing deal with Swiss regulators; Novartis gets jump on bird flu vax; Teva starts cuts;

@FiercePharma: More layoffs for $LLY: Eli Lilly to cut 100s of sales people in neuroscience, CV and men's health. Report | Follow @FiercePharma

@EricPFierce: C'est la vie. Sanofi finds the politics of downsizing in France a war of attrition. Report | Follow @EricPFierce

> Drugmakers have struck a deal with the Swiss government to accept lower payments in exchange for a promise of reducing drug approval times to as few as 60 days. Story

> ThromboGenics' partner Alcon has launched Jetrea (ocriplasmin), the first medicine for the treatment of vitreomacular traction (VMT) in the U.K. More

> Novartis ($NVS) is preparing for manufacturing of a new vaccine to fight the newest strain of bird flu through a faster process that has allowed government-backed researchers to begin testing a "seed" strain of the virus made from the genetic code posted on the Internet. Story

> Teva Pharmaceutical Industries ($TEVA) has started the process of cutting costs by improving procurement costs and reducing the footprint of its manufacturing network, CEO Jeremy Levin said. Story

> The FDA has approved Warner Chilcott's ($WCRX) 200 mg strength Doryx delayed-release antibiotic tablets, and the company intends to launch them in the U.S. in July. Release

> BTG's Varisolve treatment for varicose veins has been accepted for review by the FDA, putting it on track for potential approval and launch during the first half of 2014. Story

Medical Device News

@FierceMedDev: Dx startup On-Q-ity shuts down. DxExtra story | Follow @FierceMedDev

@MarkHFierce: Altura Medical drew in $6M in new financing for AAA stent graft develpment, according to a regulatory filing. Story | Follow @MarkHFierce

 @DamianFierce: Boston Scientific is launching a new, FDA-approved neuromodulation device for chronic back pain. Article | Follow @DamianFierce

> Medtronic launches FDA-targeted study for pain devices. News

> Life Tech snags Korean reagents outfit amid bidding war. News

> Med tech industry blasts Obama's proposed FY 14 budget. Item

Biotech News

@FierceBiotech: Firm ranks top 5 biotech deals in evolving pharma R&D landscape. Report | Follow @FierceBiotech

@JohnCFierce: Another thought on $GSK: If it gets over tox issue, drisapersen is probably headed for approval, barring a nasty efficacy surprise in Ph3. | Follow @JohnCFierce.

@RyanMFierce: Just heard from ex-FDA CIO Eric Perakslis. We'll have more on his next move soon, hopefully. News on his departure: Story | Follow @RyanMFierce

> Firm ranks top 5 biotech deals in evolving pharma R&D landscape. Report

> Boehringer Ingelheim fuels gene therapy startup focused on eye diseases. Article

> GlaxoSmithKline measures 38-meter leap over placebo in Duchenne walking test. News

And Finally... According to a new report from orphan drug specialist Shire ($SHPG), it can take more than 5 to 7 years for a patient with a rare disease to receive a proper diagnosis, averaging visits to 8 doctors on average and generally involving two or three 2-3 misdiagnoses before landing on the correct one. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.